康艾注射液联合紫杉醇、替吉奥、奥沙利铂化疗对进展期胃癌预后的影响

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (642 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要目的观察康艾注射液联合化疗对诱导型血红素氧合酶-1(Hemeoxygenase-1, HO-1)阳性进展期胃癌患者预后的影响。方法将60例血红素氧合酶阳性进展期胃癌患者随机分为实验组和对照组,每组 30 例,实验组予以康艾注射液联合紫杉醇、替吉奥、奥沙利铂方案治疗,对照组应用紫杉醇、替吉奥、奥沙利铂方案化疗。4个周期化疗后进行疗效评价及HO-1检测。结果实验组1年、2年生存率(75.2%、22.3%)均高于对照组(59.3%、15.4%),差异有统计学意义(P＜0.05)。KPS评分提高10分比例,实验组高于对照组,差异有统计学意义(P＜0.05)。结论康艾注射液对HO-1阳性进展期胃癌有治疗作用,能抑制胃癌组织中HO-1的表达,减轻患者不良反应。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵玲俊
	姜丽真
	王大庆
	刘彦同
	张清泉

关键词 ：康艾注射液, 进展期胃癌, 化疗, 诱导型血红素氧合酶, 预后

Abstract：Objective To observe the effect of Kang Ai injection combined with chemotherapy on heme oxygenase 1 (HO-1), positive outcomes in patients with advanced gastric cancer. Methods Sixty patients with positive heme oxygenase and advanced gastric cancer by were randomly divided into study group and control group, 30 patients in each group. The study group received Kang Ai injection in combination with paclitaxel, tegafur, oxaliplatin. The control group took paclitaxel, tegafur, oxaliplatin. After four cycles of chemotherapy, curative effect evaluation and HO-1 was tested. Results In the study group, strong positive rate of HO-1(24.0%, 74.3%), 1 year survival rate (74.3%, 52.1%), and 2 year survival rate(20.2%, 11.0%)were higher those in the control group, KPS increased by more than 10 points(70%, 15%),the differences between the two groups had statistical significance(P＜0.05). Conclusions Kang Ai injection therapy for advanced gastric cancer can inhibit the expression of gastric cancer tissues HO-1, and reduce the side effects, improve the prognosis of patients, and prolong the survival period.

Key words： Kang Ai injection advanced gastric cancer chemotherapy emeoxygenase-1 prognosis

收稿日期: 2016-04-13

ZTFLH:

R735.2

基金资助:衡水市科技计划项目(14006A)

作者简介: 赵玲俊,硕士,副主任医师。

引用本文:

赵玲俊, 姜丽真, 王大庆, 刘彦同, 张清泉. 康艾注射液联合紫杉醇、替吉奥、奥沙利铂化疗对进展期胃癌预后的影响[J]. 武警医学, 2016, 27(9): 900-902. ZHAO Lingjun, JIANG Lizhen, WANG Daqing, LIU Yantong, and ZHANG Qingquan. Effect of Kang Ai injection combined with paclitaxel, tegafur, oxaliplatin on prognosis of advanced gastric cancer. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(9): 900-902.

链接本文:

http://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 http://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2016/V27/I9/900

[1]	周吉昌.实用肿瘤内科学[M].2版.北京:人民卫生出版,2011:589.
[2]	Siegel R, Naishadham D, Jemal A. Cacer statistics,2013 [J]. CA Cancer J Clin,2013,63(1): 11-30.
[3]	赵玲俊,王丽华,刘丽娜,等.HO-1在胃腺癌中表达[J].中国现代医生,2011,49(32):93-95.
[4]	刘艳,金延安,刘俐敏,等. 胃癌组织中微血管密度与H0-1的表达及其临床意义[J]. 湖北科技学院学报,2012,26(6):477-479.
[5]	王尧. 在结直肠印戒细胞癌的表达及意义[J]. 转化医学电子杂志,2014,1(4):106-109.
[6]	程力,张黎,李乐平,等.抑制HO-1基因表达对人胃癌细胞系SGC-7901的影响[J].中国现代普通外科进展,2010,13(7):527-533.
[7]	田飞,张黎,郭琼行,等.血红素加氧酶-1及Toll样受体2/4在直肠癌组织中的表达及意义[J].中国现代普通外科进展,2008,11(3):248-254.
[8]	刘祉莉,袁谭蓉.中药及其化学成分对 P-gp 的抑制作用在肿瘤 MDR 的应用前景[J]. 医学信息,2015,3(10):247-248.
[9]	孙文吉,路丹. 中药逆转乳腺癌耐药研究进展[J]. 肿瘤研究与临床,2015,27(2):142-144.
[10]	樊慧婷,林洪生. 康艾注射液治疗肿瘤临床应用概况[J]. 肿瘤防治研究,2014,41(9):1045-1048.
[11]	王志海. 康艾注射液对恶性肿瘤化疗患者肾脏功能保护的影响[J].中国医药指南,2014,12(23):271-272.
[12]	安广文,安爱军,叶进科,等. 康艾注射液对中晚期胃恶性肿瘤化疗增效减毒作用及安全性评价[J]. 现代中西医结合杂志,2012,21(27):3009-3011.
[13]	邵树巍,叶兴涛.康艾注射液对中晚期胃癌生活质量的影响[J].中华中医药杂志, 2013,28(2): 554-556.
[14]	杨静,徐磊. 康艾注射液抗癌症恶病质的临床观察[J].中国中医药现代远处远程教育,2014,12(22):14-15.
[15]	张玉人,董倩.康艾注射液治疗消化系统肿瘤的研究概况[J].中国中西医结合外科杂志,2014,1(1):97-100.